Journal
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY
Volume 12, Issue -, Pages 2515-2529Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/DMSO.S229802
Keywords
oral semaglutide; type 2 diabetes; treatment; glucagon-like peptide 1
Categories
Funding
- National Institute of Health Research
- Faculty of Medicine, Prince of Songkla University, Thailand
- BHF
- Diabetes UK
- NIHR
- Abbott Diabetes Care
- Avacta
Ask authors/readers for more resources
In recent years, newer drug classes for the treatment of type 2 diabetes mellitus have been released with significant effects on glucose lowering and weight reduction. One of the most promising classes in achieving these goals has been the glucagon-like peptide (GLP)-1 agonists. However, a difficulty with the use of these agents is the need for subcutaneous injections, which can be inconvenient to individuals living with type 2 diabetes. More recently, a GLP-1 agonist has been developed, semaglutide, that can be administered orally which has at least similar effects to the subcutaneous preparation from which this compound is derived. In this review article, we discuss the glycemic and cardiovascular effects of the GLP-1 agonists with special emphasis on oral semaglutide and the potential role of this therapy in individuals with type 2 diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available